Exploring the Mechanism of Myrrh in the Treatment of Breast Cancer Based on Network Pharmacology and Cell Experiments
Authors:
- 15 August 2024
- journal article
- research article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 104 (2) , e14604
Abstract
This study aimed to investigate the mechanism of action of myrrh in breast cancer (BC) treatment and identify its effective constituents. Data on the compounds and targets of myrrh were collected from the TCMSP, PubChem, and Swiss Target Prediction databases. BC‐related targets were obtained from the Genecard database. A protein–protein interaction (PPI) analysis, gene ontology (GO) enrichment, and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were conducted on the intersecting targets of the disease and drug. The key targets of myrrh in BC treatment were identified based on the PPI network. The active constituents of myrrh were determined through reverse‐screening using the top 20 KEGG pathways. Macromolecular docking studies, molecular dynamic (MD) simulations, and cell assays were utilized to validate the active constituents and critical targets. Network pharmacology indicated that VEGFA, TP53, ESR1, EGFR, and AKT1 are key targets of myrrh. Pelargonidin chloride, Quercetin, and Naringenin were identified as the active constituents of myrrh. Macromolecular docking showed that Quercetin and Naringenin have strong docking capabilities with ESR1. The results of MD simulation experiments align with those of molecular docking experiments. Cell and western blot assays demonstrated that Quercetin and Naringenin could inhibit MCF‐7 cells and significantly reduce the expression of ESR1 protein. The findings reveal the active constituents, key targets, and molecular mechanisms of myrrh in BC treatment, providing scientific evidence that supports the role of myrrh in BC therapy. Furthermore, the results suggest that network pharmacology predictions require experimental validation for reliability.Keywords
Funding Information
- Jinan Science and Technology Bureau
This publication has 31 references indexed in Scilit:
- Novel Ziyuglycoside II derivatives inhibit MCF-7 cell proliferation via inducing apoptosis and autophagyBioorganic Chemistry, 2023
- The Relation of VEGFA, VEGFR2, VEGI, and HIF1A Genetic Variants and Their Serum Protein Levels with Breast Cancer in Egyptian PatientsBiochemical Genetics, 2023
- In vivo imaging of mammary epithelial cell dynamics in response to lineage-biased Wnt/β-catenin activationCell Reports, 2022
- Estrogen Receptor Gene Polymorphism as a Possible Genetic Risk Factor for Treatment Response in ER-Positive Breast Cancer PatientsBiochemical Genetics, 2022
- IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer MetastasisCancer Cell, 2020
- Anatomy and Physiology of the Breast during Pregnancy and Lactation2020
- The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approachesCellular Oncology, 2020
- Design, synthesis, anti-inflammatory, cytotoxic and cell based studies of some novel side chain analogues of myrrhanones A & B isolated from the gum resin of Commiphora mukulBioorganic Chemistry, 2019
- A Cytoplasmic NF-κB Interacting Long Noncoding RNA Blocks IκB Phosphorylation and Suppresses Breast Cancer MetastasisCancer Cell, 2015
- Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancerCritical Reviews in Oncology/Hematology, 2014